Pharmechceutics Ltd., Ware, Hertfordshire, United Kingdom.
Insmed, Inc., Bridgewater, New Jersey.
J Aerosol Med Pulm Drug Deliv. 2020 Jun;33(3):127-132. doi: 10.1089/jamp.2020.1597. Epub 2020 Mar 16.
In May 2019, the International Society for Aerosols in Medicine (ISAM) and the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) held a one-day workshop on digital health tools for respiratory therapies, with speakers representing views of patients, pharmaceutical and technology companies, physicians, and payors. Workshop presentations, audience discussions, and research of relevant literature form the basis of this article. Conversations and publications to date illustrate the broad, and growing, interest in digital technologies, but also highlight a few gaps. The key messages are: (1) There are many great technologies, from simple to complex, but there is still an imperfect understanding of the problems that digital tools need to solve. The current approach often starts with a technology "solution" and then identifying the problems that it could address. This is a poor design practice: the offered technology may not represent the optimum solution to that problem; and that "problem" itself may not represent issues that patients or the health care system deem to be of high priority. (2) Respiratory medicine currently lacks widely accepted and easily measured biomarkers or hand-held diagnostic technologies that could be commercialized for complex/heterogeneous diseases such as asthma (unlike in other areas, e.g., diabetes). (3) There are no obvious solutions that integrate the perspectives of the many stakeholders-from patients to physicians to payors-to make the new field commercially viable, and the incentives of various parties in the health care system are misaligned. (4) A continued dialog, information sharing, mutual education, and collaborations are important in bringing the promise of digital respiratory medicine to fruition. Digital tools for diagnosis and management of respiratory conditions are an active area of research and development but long-term success in this field will depend on identifying real needs, and integrating the often-diverging interests of the various partners in each country's health care system.
2019 年 5 月,国际气溶胶医学学会(ISAM)和国际药剂气溶胶监管与科学联合会(IPAC-RS)就呼吸疗法的数字健康工具举办了为期一天的研讨会,发言者代表了患者、制药和技术公司、医生和支付方的观点。研讨会报告、观众讨论和相关文献研究构成了本文的基础。迄今为止的讨论和出版物表明,人们对数字技术的兴趣广泛且日益浓厚,但也突出了一些差距。关键信息如下:(1)有许多很棒的技术,从简单到复杂,但对于数字工具需要解决的问题,仍存在理解不完善的情况。目前的方法通常从技术“解决方案”开始,然后确定它可以解决的问题。这是一种糟糕的设计实践:所提供的技术可能不是解决该问题的最佳方案;而且该“问题”本身可能不是患者或医疗保健系统认为优先级较高的问题。(2)呼吸医学目前缺乏广泛认可且易于测量的生物标志物或手持式诊断技术,这些技术可应用于哮喘等复杂/异质疾病(与其他领域不同,例如糖尿病)。(3)没有明显的解决方案可以整合众多利益相关者的观点,从患者到医生再到支付方,使新领域具有商业可行性,而且医疗保健系统中各方的激励措施并不一致。(4)持续对话、信息共享、相互教育和合作对于实现数字呼吸医学的承诺非常重要。用于诊断和管理呼吸状况的数字工具是一个活跃的研发领域,但该领域的长期成功将取决于确定实际需求,并整合每个国家医疗保健系统中各个合作伙伴经常存在分歧的利益。